BioNet-Asia is a Biotech company with a manufacturing base in Asia and with clinical and business operations in Europe, Asia and Australia.
Because we believe sharing vaccine expertise can accelerate the global development of innovative vaccines, we keep on building long-term and fruitful collaborations with universities, research institutes, biotech companies and vaccine manufacturers around the world.
In its state-of-the-art vaccine plant in Thailand, BioNet is also building a unique expertise in genetic engineering, protein conjugation, cell-culture and vaccine formulation. The company has developed a broad pipeline with ten products in R&D and clinical stages, including vaccines and recombinant proteins such as CRM197 protein carrier, dengue and hepatitis B vaccines.
The company has transferred the technology to produce Hib meningitis vaccine which is now commercialized as a pentavalent vaccine in Asia.
BioNet produces recombinant acellular pertussis vaccines using a proprietary technology. Our vaccines are manufactured in accordance to Good Manufacturing Practices (GMP) PIC/S standards, and tested at each manufacturing step as per pharmacopeia requirements using established validated assays in our own quality control and testing facilities.
More than 150 highly-skilled employees develop the vaccines of tomorrow, from conception to distribution throughout each development stage: research, non-clinical studies, clinical trials, manufacturing and post-marketing surveillance to ensure the safety, immunogenicity and effectiveness of our vaccines.